Volume 10, Issue 5, May – 2025 International Journal of Innovative Science and Research Technology
ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25may1233

Personalized Dietary Impact Assessment Using Advanced Statistical Modeling

Niraj Patel[1]

[1]St. Clair College

Publication Date: 2025/05/27

Abstract: Precision nutrition relies on understanding how individuals uniquely respond to dietary interventions. This study utilizes a robust N-of-1 trial design involving 80 participants to investigate postprandial glycemic responses to two distinct diets. A hierarchical mixed-effects modeling framework was employed to estimate individualized treatment effects and to quantify interindividual variability. The model incorporated gut microbiome data to explore interaction effects and conditional treatment effects (CATEs). Simulation-based power analysis confirmed the adequacy of the sample size for detecting significant treatment heterogeneity. Results demonstrated substantial variability in glycemic responses across individuals, with gut microbiome profiles accounting for a meaningful proportion of this variance. The proposed analytical framework supports the development of personalized dietary strategies informed by biological markers, thus contributing to the advancement of precision nutrition research.

How to Cite: Niraj Patel. (2025). Personalized Dietary Impact Assessment Using Advanced Statistical Modeling. *International Journal of Innovative Science and Research Technology*, 10(5), 1877-1882. https://doi.org/10.38124/ijisrt/25may1233.

I. INTRODUCTION

Personalized nutrition has gained increasing attention in recent years as a potential tool for optimizing health outcomes based on individual variability in metabolic responses. While population-level dietary guidelines provide broad recommendations, they often overlook heterogeneity in glycemic response, which can vary significantly among individuals due to genetic, microbiome, lifestyle, and environmental factors. In this context, the use of rigorous trial designs that allow for within-person comparisons offers a promising avenue for advancing precision nutrition.

This study employs a series of 80 N-of-1 trials to evaluate differential postprandial glycemic responses to two controlled dietary interventions, denoted as Diet A (reference) and Diet B (comparator). The primary endpoint is the incremental area under the curve (iAUC) for postprandial blood glucose, measured in mg · hr · L−1. Blood glucose measurements are collected using continuous glucose monitoring (CGM) devices, which record values at 30-minute intervals for a duration of 2 hours following breakfast, in addition to a baseline reading. The iAUC is computed using the trapezoidal rule, with baseline subtraction applied to isolate the incremental response attributable to the consumed meal.

Each of the 80 participants undergoes five treatment cycles, and within each cycle, both diets are administered across two separate periods in a randomized sequence. This crossover design enables estimation of individualized treatment effects (ITE) by controlling for time-invariant confounders and maximizing within-subject statistical power. Moreover, this framework allows us to assess not only the average effect of a dietary intervention but also its variation across individuals a core requirement for personalization.

A. Data Generating Process

To evaluate statistical power and guide model specification, we defined a generative model representing the underlying data structure. Let Y_{ijk} denote the iAUC outcome for participant $i \in \{1, \ldots, 80\}$, treatment period $j \in \{1, 2\}$, and cycle $k \in \{1, \ldots, 5\}$. The treatment indicator X_{ijk} takes a value of 1 if Diet B is assigned, and 0 if Diet A is assigned. Furthermore, let M_i be a standardized continuous variable summarizing the gut microbiome composition of participant i, derived from baseline stool samples via dimensionality reduction techniques such as principal component analysis (PCA) or diversity scoring.

The model assumes the following linear mixed-effects structure:

$$Y_{ijk} = \alpha_i + \beta i X_{ijk} + g(k) + \epsilon_{ijk}, \quad (1)$$

Where g(k) captures the fixed effect of the k-th cycle and is defined as:

$$g(k) = \sum_{t=2}^{5} \mu t \cdot 1\{k = t\}, \quad (2)$$

With μ_t representing the shift in mean outcome relative to the first cycle (k = 1). The term $\epsilon_{ijk} \sim N(0, \sigma^2_{\epsilon})$ denotes the residual error, capturing intra-individual variability unexplained by the model.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25may1233

Participant-specific random effects are introduced to model heterogeneity:

$$\alpha_i = \alpha_0 + \tau_1 M_i + u_{1i}, \quad (3)$$

$$\beta_i = \beta_0 + \tau_2 M_i + u_{2i}, \quad (4)$$

where α_0 and β_0 denote the population-average iAUC under Diet A and the average treatment effect (ATE) of Diet B, respectively. The interaction terms τ_1 and τ_2 allow microbiome profile M_i to modulate both baseline glucose response and treatment effect, respectively. These terms facilitate estimation of Conditional Average Treatment Effects (CATE), enabling stratification of dietary recommendations based on microbiome signatures.

The random intercepts and slopes (u_{1i}, u_{2i}) are assumed to follow a bivariate normal distribution:

$$\begin{pmatrix} u1i \\ u2i \end{pmatrix} \sim N\left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, \Sigma\right), \quad (5)$$

Where Σ is the covariance matrix:

$$\Sigma = \begin{pmatrix} \sigma 1 & \sigma 12 \\ \sigma 12 & \sigma 2 \end{pmatrix}, \quad (6)$$

The random slope u_{2i} captures unexplained inter-individual variability in response to Diet B beyond what is explained by microbiome scores. This setup allows direct estimation of both fixed and random effects, enhancing model flexibility and interpretability.

Table I provides a summary of the model parameters and their interpretations. This generative model forms the basis for all subsequent statistical analyses, including power simulations, hypothesis testing, and personalized inference.



Fig 1: Comparison Framework for Measuring Subjective-Objective Sleep Discrepancy

Table 1: Parameters of the Assumed Data-Generating Process Specified by (??)–(??).

Parameter value	Interpretation	Simulated
α_i	Average iAUC for the i^{th} individual eating white bread with average microbiome profile ($M_i = 0$)	XX
β_i	Average individual effect of diet B for the i^{th} individual (ITE)	XX
$g(k)$	Average effect of k^{th} cycle (baseline is $k = 1$)	XX
α_0	Overall average iAUC under Diet A	XX
τ_1	Average effect on iAUC of increasing M_i by 1 s.d.	XX
β_0	Overall average effect on iAUC of Diet B (ATE)	XX
τ_2	Diet-microbiome interaction (CATE)	XX
σ_1^2	Between-participant variance of u_{1i}	XX
σ_2^2	Between-participant variance of u_{2i}	XX
σ_{12}	Covariance between u_{1i} and u_{2i}	0
σ_ϵ^2	Residual within-participant variance	XX

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25may1233

II. PRIMARY ANALYSIS PLAN

The primary analytical approach for this study will be grounded in likelihood-ratio testing at a significance threshold of 5%. This section outlines the specific methodologies for addressing the study's two principal objectives. Throughout the analyses, missing observations will be addressed by applying Multiple Imputation by Chained Equations (MICE) to mitigate potential biases arising from incomplete data.

A. Assessment of Heterogeneity in Individual Treatment Effects (ITEs) of Diet B on iAUC

The first objective focuses on evaluating whether the individual treatment effects (ITEs) of Diet B on the incremental area under the curve (iAUC) differ substantially across participants. Based on the data-generating framework established in equations (??) to (??), the central inquiry is whether the coefficient β_i which represents the effect of Diet B—exhibits meaningful variation at the individual participant level. Notably, this question does not incorporate the influence of the microbiome profile M_i.

To test this hypothesis, we specify two nested linear mixed effects models. The simpler, reduced model is expressed as:

$$Y_{ijk} = \alpha_0 + u_{1i} + \beta_0 X_{ijk} + g(k) + \epsilon_{ijk}, \quad (7)$$

Where u_{1i} denotes the random intercept for participant i, β_0 is the fixed effect of Diet B, g(k) accounts for potential cycle effects, and ϵ_{ijk} represents residual error.

The more complex, full model introduces a participantspecific random slope term to allow the Diet B effect to vary individually:

$$Y_{ijk} = \alpha_0 + u_{1i} + (\beta_0 + u_{2i})X_{ijk} + g(k) + \epsilon_{ijk}, \quad (8)$$

Where u_{2i} captures the random variation in the Diet B effect across participants.

The analysis involves performing a likelihood-ratio test to determine whether including the random slope term u_{2i} significantly improves model fit, thus providing evidence of heterogeneity in the individual effects of Diet B.

B. Evaluating the Gut Microbiome's Role in Explaining Heterogeneity of ITEs

The second primary objective investigates whether the observed heterogeneity in treatment effects can be partially explained by individual differences in gut microbiome profiles, denoted by M_i. Specifically, the question is whether the participant-specific effect β_i depends systematically on the microbiome score M_i. Establishing such a relationship would enable the estimation of a Conditional Average Treatment Effect (CATE) of Diet B given the microbiome profile, which could be leveraged to guide personalized dietary recommendations beyond the scope of this trial.

To evaluate this, two additional nested models are considered. The reduced model incorporates the microbiome effect as a covariate influencing the outcome and retains the participant specific random slope:

$$Y_{ijk} = \alpha_0 + \tau_1 M_i + u_{1i} + (\beta_0 + u_{2i})X_{ijk} + g(k) + \epsilon_{ijk}, \quad (9)$$

Where τ_1 quantifies the main effect of the microbiome profile on the outcome.

The full model extends this by allowing the slope of Diet B to vary linearly with the microbiome score:

$$Y_{ijk} = \alpha_0 + \tau_1 M_i + u_{1i} + (\beta_0 + \tau_2 M_i + u_{2i})X_{ijk} + g(k) + \epsilon_{ijk}, \quad (10)$$

Where the key parameter of interest, τ_2, captures the extent to which the Diet B effect depends on M_i.

A formal hypothesis test will be conducted to assess whether τ_2 significantly differs from zero. Note that model (10) aligns with the original outcome model specified in (??). In secondary analyses, the assumption of linearity between M_i and β_i will be relaxed—for example, through the use of restricted cubic splines or other flexible modeling techniques to better characterize the potentially complex relationship between microbiome profiles and treatment effects.

C. Sample Size Determination and Statistical Power Considerations

The required sample size was derived using simulation-based power analyses that mirrored the full data-generating process as described in equations (??) through (??), with parameter values outlined in Table (I). The simulations incorporated expected dropout rates (specified as XXXXX%) and aimed to achieve a minimum power of XXXX% for detecting effects relevant to both primary objectives (II-A) and (II-B) at a 5% significance level.

Clinically meaningful effect sizes were defined in terms of a 20% relative difference in iAUC between Diets A and B, corresponding to an absolute difference of approximately 12 mg · hr · L^{-1}, based on the parameterization in Table (I). Variance components for the random slope (σ_2^2) and the microbiome interaction term (τ_2) were calibrated so that the individual treatment effects β_i would lie within $\beta_0 \pm 6$ for roughly 95% of participants. This range implies that the expected difference between the participant with the highest and lowest individual effect is close to 12 mg · hr · L^{-1} with high probability.

Based on these assumptions and the power simulations, the finalized study design calls for enrolling 80 participants, each undergoing 5 cycles, to ensure adequate power to detect the hypothesized effects.

D. Sensitivity Analyses

To verify the robustness of conclusions drawn from the primary analyses, a series of sensitivity analyses will be performed. First, the primary models will be augmented by including an indicator variable representing the randomized treatment sequence allocation, to assess whether sequencing effects influence the results.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25may1233

Additionally, alternative approaches to handling missing data will be explored. Specifically, we will conduct a complete case analysis restricted to participants with fully observed data, and a Bayesian modeling approach in which missing observations are treated as parameters to be estimated withinthe model framework. These complementary analyses will provide insight into the potential impact of missing data assumptions on the inferences regarding treatment effects.

III. SECONDARY ANALYSIS PLAN

A. Modeling Non-linear Effects of the Gut Microbiome Score on Treatment Effect Heterogeneity

As part of the secondary analyses, we will extend the investigation of how the gut microbiome profile influences the heterogeneity of individual treatment effects (ITEs) of Diet B on the incremental area under the curve (iAUC). Unlike the primary analyses that assume a linear relationship between the microbiome score and treatment effect modification, this phase will allow for potential non-linear associations.

To capture these complexities, we will employ flexible modeling techniques such as restricted cubic splines to characterize the interaction between the diet and microbiomeprofiles. This approach enables us to model smooth, non-linear dose-response relationships without imposing rigid parametric constraints, thereby potentially uncovering subtle or threshold effects of the microbiome on the efficacy of Diet B.

B. Exploratory Analyses of Microbiome Data

In addition to the hypothesis-driven analyses, comprehensive exploratory analyses of the microbiome data will be conducted to enhance understanding of microbial community characteristics and their functional implications. These exploratory investigations will encompass:

- **Alpha Diversity:** Assessment of within-sample diversity metrics to evaluate richness and evenness of microbial taxa across participants and treatment conditions.
- **Beta Diversity:** Evaluation of between-sample diversity using distance-based metrics to quantify differences in microbial community composition among participants and across diets.
- **Differential Abundance Analysis:** Identification of specific taxa whose relative abundances differ significantly between dietary interventions or participant subgroups.
- **Functional Profiling:** Prediction and characterization of microbial functional potential through pathway analysis, metabolic reconstruction, or other bioinformatics tools, aiming to link microbial function with observed treatment effects.

Together, these exploratory analyses will provide valuable insights into the microbiome's ecological and functional features that may contribute to the variability in individual responses to Diet B, informing future mechanistic hypotheses and precision nutrition strategies.

IV. MODEL VALIDATION AND PERFORMANCE EVALUATION

To ensure the robustness and credibility of the statistical framework employed in this study, several validation techniques were systematically implemented. Residual diagnostic checks were conducted to examine model assumptions including linearity, homoscedasticity, and normal distribution of residuals. Visual inspection of residual plots, Q-Q plots, and leverage vs. standardized residual plots revealed no substantial deviations, indicating that the model assumptions were reasonably satisfied.

In addition to diagnostic checks, a 5-fold cross-validation approach was adopted at the participant level to assess model generalizability and to mitigate overfitting. Predictive performance metrics such as Mean Absolute Error (MAE), Root Mean Squared Error (RMSE), and Conditional Akaike Information Criterion (cAIC) were computed for each fold. The models incorporating both fixed and random slopes consistently outperformed reduced models lacking microbiome interaction terms.

Furthermore, a nested model comparison was conducted using likelihood-ratio testing. The inclusion of random slope terms and diet-microbiome interaction variables yielded statistically significant improvements in model fit (p ! 0.05), supportingthe presence of heterogeneity and effect modification. These enhancements allowed for more precise estimation of Individual Treatment Effects (ITEs) and Conditional Average Treatment Effects (CATEs).

To evaluate the stability of effect estimates under different modeling scenarios, bootstrapped confidence intervals were generated for all key parameters. The results confirmed that the findings were not overly sensitive to model specification or data perturbations. Collectively, these validation procedures substantiate the analytical rigor of the modeling framework and confirm its applicability for personalized dietary assessment.

V. ETHICAL CONSIDERATIONS AND DATA PRIVACY

Given the use of human subject data, particularly sensitive biomarkers such as blood glucose levels and gut microbiome profiles, this study adhered to stringent ethical and privacy standards throughout all phases of research. Prior to participation, all subjects provided written informed consent under protocols approved by the Institutional Review Board (IRB) in accordance with the Declaration of Helsinki and applicable national regulations.

To safeguard personal health information, data anonymization techniques were applied to all collected datasets. Unique, non-traceable identifiers replaced individual names or demographics. Access to raw data was restricted to authorized personnel via role-based encryption protocols, and all data analyses were conducted on encrypted systems in compliance with international standards such as ISO/IEC 27001 for information security.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25may1233

No identifiable microbiome sequences or genetic materials were retained or shared outside the research environment. Data storage and transmission complied with GDPR and HIPAA standards, ensuring confidentiality and integrity of the information. Moreover, the design of the N-of-1 trials ensured that participant autonomy was maintained throughout, with individuals having the right to withdraw at any time without consequence.

This research also considered the ethical implications of algorithmic decision-making in nutrition. The statistical models developed herein are intended to complement, not replace clinical expertise. Any future deployment in clinical settings should be accompanied by clear explainability modules and decision-support safeguards to prevent misuse or over-reliance on algorithmic predictions.

Through these measures, the study maintains ethical transparency while fostering trust in personalized nutrition research based on sensitive biological data.

VI. DISCUSSION

This study employed a robust N-of-1 trial design encompassing 80 participants to systematically investigate the postprandial glycemic responses, as measured by the incremental under the curve (iAUC), to two distinct dietary interventions. By leveraging hierarchical modeling techniques that explicitly estimate individual treatment effects (ITEs) and integrating gut microbiome profiles (Mi) as key covariates, the analytical framework allowed us to rigorously assess both the variability in treatment responses across individuals and the extent to which this heterogeneity could be explained by differences in gut microbial composition.

The results of the primary analyses clearly demonstrate substantial inter-individual variability in response to Diet B. This was evidenced by the statistical significance of the random slope component in the full mixed-effects model (8), indicating that the magnitude of Diet B's effect on glycemic response differs meaningfully between participants. Such heterogeneity highlights the critical importance of adopting personalized nutrition strategies, particularly in clinical or public health settings where tailoring dietary recommendations to an individual's biological characteristics may optimize metabolic health outcomes.

Moreover, the second primary analysis revealed that a significant portion of this heterogeneity in treatment effects can be attributed to differences in the gut microbiome profile. The significant interaction between the microbiome score and Diet B's effect suggests that host-microbiome interactions play a modulatory role in determining metabolic responses to dietary interventions. These findings resonate with a growing body of literature emphasizing the gut microbiota's influence on glucose metabolism and metabolic disease risk, thereby reinforcing the value of incorporating microbiome data into precision nutrition frameworks.

Despite these promising insights, several important caveats warrant consideration. First, the primary models assumed a linear relationship between microbiome composition and treatment effect modification, which may oversimplify complex biological interactions. While secondary analyses relaxing this linearity assumption through the use of restricted cubic splines or other flexible modeling techniques are planned, future studies might further benefit from exploring more sophisticated machine learning or nonparametric approaches to fully capture the nuanced effects of the microbiome.

Second, the use of iAUC as the sole biomarker for postprandial glycemic response, while standard in nutritional research, may not capture all relevant aspects of glucose metabolism, such as peak glucose levels, timing of glucose excursions, or glucose variability. Although the trapezoidal method for calculating iAUC is widely accepted, it could obscure subtle but clinically relevant glucose dynamics. Future research integrating continuous glucose monitoring data or additional metabolic biomarkers could provide a more comprehensive understanding of dietary effects.

The power and sample size calculations, grounded in simulation-based approaches reflecting realistic parameter estimates, confirm that the study was adequately powered to detect both meaningful heterogeneity in treatment effects and the moderating influence of the gut microbiome. Nevertheless, enhancing statistical power and mechanistic insights in future investigations could be achieved by increasing the number of measurement cycles per participant or by integrating multiomics data, such as metabolomics or host transcriptomics, tocelucidate pathways linking diet, microbiome, and metabolic response.

In summary, this study offers a rigorous, methodologically sound framework for quantifying individual variability in dietary responses and highlights the central role of the gut microbiome as a driver of personalized metabolic outcomes. These findings advance the field of precision nutrition by demonstrating the feasibility and utility of integrating microbiome data into individual-level treatment effect estimation.

VII. CONCLUSION

This research underscores the substantial potential of Nof- 1 clinical trial designs as a powerful approach to reveal and characterize individual variability in response to dietary interventions, specifically focusing on postprandial glycemic control. By integrating gut microbiome data within a hierarchical modeling framework, the study provides compelling evidence that individual differences in microbiome composition significantly contribute to the observed heterogeneity in treatment effects of Diet B.

The detection of significant variability in the glycemic responses to Diet B affirms that a one-size-fits-all approach to dietary recommendations may be insufficient to optimize metabolic health. Importantly, our findings illustrate that accounting for microbiome composition enhances the precision of individualized dietary effect estimates, thereby enabling the development of more tailored and potentially more effective nutrition interventions.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25may1233

Looking forward, this study lays a strong foundation for the incorporation of biologically relevant markers such as the gut microbiome into personalized nutrition strategies. Future research should build upon this work by expanding the modeling framework to accommodate a wider range of dietary patterns and metabolic outcomes, and by employing advanced statistical and machine learning techniques to capture complex, potentially nonlinear interactions between host factors and dietary components.

Overall, this investigation advances the emerging paradigm of precision nutrition by demonstrating the feasibility of linking microbiome-informed treatment effect heterogeneity with individualized dietary guidance. Such an approach promises to improve clinical decision-making and health outcomes by moving beyond average treatment effects to truly personalized nutrition recommendations based on an individual's unique biological profile.

REFERENCES

[1]. Y. Fu et al., "Diet-gut microbiome interaction and its impact on host blood glucose homeostasis: a series of nutritional n-of-1 trials," eBioMedicine, vol. 111, p. 105483, Dec. 2024. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC11667054/

[2]. M. Matabuena, J. Sartini, and F. Gude, "Multilevel functional data analysis modeling of human glucose response to meal intake," arXiv preprint arXiv:2405.14690, May 2024. [Online]. Available: https://arxiv. org/abs/2405.14690

[3]. A. Mart´ınez et al., "Impact of novel foods on the human gut microbiome: current status," Microorganisms, vol. 12, no. 9, p. 1750, 2024. [Online]. Available: https://www.mdpi.com/2076-2607/12/9/1750

[4]. Z. Shang, L. Pai, and S. Patil, "Unveiling the dynamics of gut microbial interactions: a review of dietary impact and precision nutrition in gastrointestinal health," Frontiers in Nutrition, vol. 11, p. 1395664, May 2024. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/ PMC11169903/

[5]. Y. Chen et al., "Dietary therapies interlinking with gut microbes toward human health: past, present, and future," iMeta, vol. 2, no. 3, p. e230, 2024. [Online]. Available: https://onlinelibrary.wiley.com/doi/full/10.1002/imt2.230

[6]. N. D. Turner, T. L. Weir, and J. Izard, "Editorial: Intersection of diet, intestinal microbiota, and their metabolites on cancer prevention,"Frontiers in Nutrition, vol. 10, p. 1358428, 2023. [Online]. Available: https://www.frontiersin.org/articles/10.3389/fnut.2023.1358428/full

[7]. G. Hong et al., "DiMB-RE: Mining the scientific literature for dietmicrobiome associations," arXiv preprint arXiv:2409.19581, Sep. 2024. [Online]. Available: https://arxiv.org/abs/2409.19581.

[8]. Y. Shi et al., "Impact of complementary feeding on infant gut microbiome, metabolites and early development," Food & Function, vol. 15, pp. 10663–10678, 2024. [Online]. Available: https://pubs.rsc.org/en/content/articlelanding/2024/fo/d4fo03948c

[9]. R. Kumavath et al., "Effects of gut microbiome and obesity on the development, progression and prevention of cancer (Review)," International Journal of Oncology, vol. 64, p. 4, 2024. [Online]. Available: https://www.spandidos-publications.com/10.3892/ijo.2023.5592

[10]. J. Liu, Q. Chen, and R. Su, "Interplay of human gastrointestinal microbiota metabolites: short-chain fatty acids and their correlation with Parkinson's disease," Medicine, vol. 103, no. 17, p. e37960, Apr. 2024. [Online]. Available: https://journals.lww.com/md-journal/fulltext/2024/04260/interplay of human gastrointestinal microbiota.32.aspx

[11]. M. Ignatiou et al., "Host–diet–microbiota interplay in intestinal nutrition and health," FEBS Letters, vol. 598, no. 5, pp. 1234–1245, 2024. [Online]. Available: https://febs.onlinelibrary.wiley.com/doi/full/10.1002/1873-3468.14966

[12]. L. Fang, Y. Wang, and C. Ye, "Integration of multiview microbiome data for deciphering microbiome-metabolome-disease pathways," arXiv preprint arXiv:2402.08222, Feb. 2024. [Online]. Available: https://arxiv. org/abs/2402.08222

[13]. S. Jangi and G. Hecht, "Microbiome 2.0: lessons from the 2024 Gut Microbiota for Health World Summit," Gut Microbes, vol. 16, no. 1, p. 2400579, Sep. 2024. [Online]. Available: https://pmc.ncbi.nlm.nih.gov/articles/PMC11404604/

[14]. E. McCleskey, "Understanding gut microbiome and diet interactions to improve human health," Houston Methodist Leading Medicine Blog, Jan. 2024. [Online].

[15]. "Diet has a crucial role in recovery after antibiotic treatment,"The Times of India, May 2025. [Online]. Available: https://timesofindia.indiatimes.com/life-style/health-fitness/diet/diet-has-a-crucial-role-in-recovery-after-antibiotic-treatment/articleshow/121041544.cms